GlobeNewswire
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
📈
AI Sentiment
Highly Positive
9/10
Latest updates and market news for EVGN
AI Sentiment
Highly Positive
9/10
Share this news page